Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
PETS 
PetMed Express Inc (PETS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/04/2025: PETS (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -3.72% | Avg. Invested days 28 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/04/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 72.50M USD | Price to earnings Ratio 351 | 1Y Target Price 3.75 |
Price to earnings Ratio 351 | 1Y Target Price 3.75 | ||
Volume (30-day avg) 211937 | Beta 0.99 | 52 Weeks Range 2.90 - 6.85 | Updated Date 04/6/2025 |
52 Weeks Range 2.90 - 6.85 | Updated Date 04/6/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.01 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 0.15% | Operating Margin (TTM) -0.85% |
Management Effectiveness
Return on Assets (TTM) 0.93% | Return on Equity (TTM) 0.36% |
Valuation
Trailing PE 351 | Forward PE 17.92 | Enterprise Value 23558476 | Price to Sales(TTM) 0.29 |
Enterprise Value 23558476 | Price to Sales(TTM) 0.29 | ||
Enterprise Value to Revenue 0.1 | Enterprise Value to EBITDA 3.13 | Shares Outstanding 20656500 | Shares Floating 16455769 |
Shares Outstanding 20656500 | Shares Floating 16455769 | ||
Percent Insiders 28.4 | Percent Institutions 45.28 |
Analyst Ratings
Rating 2 | Target Price 3.75 | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold 1 | Sell - | Strong Sell 1 | |
Strong Sell 1 |
Upturn AI SWOT
PetMed Express Inc
Company Overview
History and Background
PetMed Express, Inc. (PetMeds) was founded in 1996. It is a leading online pet pharmacy, delivering prescription and non-prescription pet medications and health products directly to consumers.
Core Business Areas
- Online Pet Pharmacy: PetMeds primarily operates as an online retailer, offering a wide array of pet medications, food, and supplies through its website and mobile app.
Leadership and Structure
PetMed Express has a board of directors overseeing the company's strategic direction. Its executive leadership team manages day-to-day operations.
Top Products and Market Share
Key Offerings
- Market Share data: Market share data is not easily or consistently published.
- Prescription Medications: Includes medications for heartworm, flea and tick prevention, arthritis, and other conditions. Elanco and Boehringer Ingelheim are competitors.
- Market Share data: Market share data is not easily or consistently published.
- Non-Prescription Medications: Includes vitamins, supplements, and over-the-counter treatments. Chewy and Amazon are competitors.
- Market Share data: Market share data is not easily or consistently published.
- Pet Supplies: Includes food, toys, and accessories. Petco and Petsmart are competitors.
Market Dynamics
Industry Overview
The pet medication and supply industry is experiencing growth driven by increasing pet ownership and a willingness to spend on pet health and well-being. The market is competitive with online retailers, brick-and-mortar stores, and veterinary clinics vying for market share.
Positioning
PetMed Express positions itself as a convenient and affordable alternative to traditional veterinary channels for pet medications and supplies. It leverages its online platform and direct-to-consumer model.
Total Addressable Market (TAM)
The US pet care market is estimated to be over $100 billion. PetMed Express' positioning allows it to tap into a portion of this market through its online pharmacy services.
Upturn SWOT Analysis
Strengths
- Established brand recognition in online pet pharmacy
- Direct-to-consumer model
- Convenient online platform
- Wide range of products
- Strong customer base
Weaknesses
- Dependence on third-party suppliers
- Competition from larger online retailers
- Potential for regulatory changes affecting online pharmacies
- Negative reviews regarding customer service and order fulfillment
Opportunities
- Expansion of product offerings
- Partnerships with veterinary clinics
- International expansion
- Development of mobile app features
- Growth of the pet insurance market
Threats
- Increased competition from online retailers
- Changes in consumer preferences
- Economic downturn affecting pet spending
- Regulatory restrictions on pet medication sales
- Supply chain disruptions
Competitors and Market Share
Key Competitors
- CHWY
- AMZN
- PETS
Competitive Landscape
PetMed Express faces competition from larger online retailers with broader product offerings and established customer bases. PetMed Express may need to focus on differentiating through specialized service or product offerings.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: PetMed Express' historical growth can be assessed by examining its revenue and customer acquisition trends over the past years. Please refer to public financial resources for this detailed data.
Future Projections: Future growth projections would require consulting analyst estimates and industry forecasts for the pet medication and supply market. Please refer to public financial resources for this detailed data.
Recent Initiatives: Recent initiatives would require monitoring company press releases, investor presentations, and industry news for strategic developments.
Summary
PetMed Express, as a specialized online pet pharmacy, leverages its direct-to-consumer model and established brand. Competition from larger retailers and potential regulatory changes pose significant challenges. Growth opportunities lie in expanding product offerings and potentially partnering with veterinary clinics. The company should focus on improving customer satisfaction and operational efficiencies.
Similar Companies
AMZN
Amazon.com Inc
AMZN
Amazon.com Inc
CHWY
Chewy Inc
CHWY
Chewy Inc
IDXX
IDEXX Laboratories Inc
IDXX
IDEXX Laboratories Inc
VET
Vermilion Energy Inc.
VET
Vermilion Energy Inc.
Sources and Disclaimers
Data Sources:
- Company filings (SEC), Industry reports, Market research, Press releases
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market share data are estimates and may vary. Consult with a qualified financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About PetMed Express Inc
Exchange NASDAQ | Headquaters Delray Beach, FL, United States | ||
IPO Launch date 1999-04-26 | President, CEO & Director Ms. Sandra Y. Campos | ||
Sector Healthcare | Industry Pharmaceutical Retailers | Full time employees 287 | Website https://www.1800petmeds.com |
Full time employees 287 | Website https://www.1800petmeds.com | ||
PetMed Express, Inc., together with its subsidiaries, operates as a pet pharmacy in the United States. The company markets prescription and non-prescription pet medications, health products, and other supplies for dogs, cats, and horses. It offers non-prescription medications and supplies, such as flea and tick control products, bone and joint care products, vitamins, treats, nutritional supplements, hygiene products, and household pet supplies; and prescription medications, including heartworm preventatives, flea and tick preventatives, arthritis, dermatitis, thyroid, diabetes, pain medications, heart/blood pressure, and other specialty medications, as well as generic substitutes. The company also sells food, beds, crates, stairs, and other pet supplies. It sells its products through its Internet website; mobile app; customer support center; and direct mail/print, which includes brochures and postcards. The company was incorporated in 1996 and is headquartered in Delray Beach, Florida.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.